2 results
Approved WMOCompleted
CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…
Approved WMORecruiting
To test whether immediate complete revascularization is non-inferior to staged (but within six weeks after index procedure) complete revascularization in ACS patients with multivessel disease